Print
October 14, 2009
Advaxis Added to Stonegate's Equity Universe
North Brunswick, NJ – October 14, 2009 – Stonegate Securities has initiated research coverage on Advaxis, Inc., (OTCBB: ADXS) the live, attenuated Listeria monocytogenes (Lm) vaccine company, last week. For more information on the research report, please contact Marco Rodriguez, CFA of Stonegate Securities at marco@stonegateinc.com and/or your local investment professional.
About the Company
Based in North Brunswick, New Jersey, Advaxis is developing proprietary Listeria monocytogenes (Lm) cancer vaccines based on technology developed by Dr. Yvonne Paterson, professor of microbiology at the University of Pennsylvania and chairperson of Advaxis’ scientific advisory board. Advaxis is developing attenuated live Lm vaccines that deliver engineered tumor antigens, which stimulate multiple simultaneous immunological mechanisms to fight cancer.
In a recent Advaxis Phase I clinical trial, a live Lm vaccine directed against the tumor-associated antigen HPV-16-E7 was safely administered to fifteen (15) women with advanced metastatic cancer of the cervix. Although this first trial of an Lm vaccine in humans was not designed or powered to prove efficacy, Advaxis believes an efficacy signal was observed that will be further explored in two (2) planned Phase II trials in the US and India in cervical cancer and its predecessor condition, cervical intraepithelial neoplasia (CIN). Advaxis now has nine (9) distinct cancer fighting constructs in various stages of development, both directly and with academic collaborators. For further information on the Company, please visit: www.advaxis.com.
About Stonegate Securities
Stonegate is a 30-year old broker/dealer headquartered in Dallas, Texas. We specialize in raising capital and moving large blocks of stock with institutional investors for companies with market capitalizations under $500 million.
About the Relationship between the Company and Stonegate Securities
Advaxis engaged Stonegate Securities (“Stonegate”) in June 2009 to act as its non-exclusive placement agent on a “best-efforts” basis in connection with one or more private placements of Advaxis equity and/or debt securities, and provide research distribution services. As compensation for such services, the Company is contracted to pay Stonegate $100,000 and a fee of seven percent (7%) of the gross proceeds from the sale of Advaxis securities to investors, identified by Stonegate; and agreed to reimburse Stonegate for out-of-pocket expenses and issue additional shares of Advaxis stock equal to three percent (3%) of the total number of securities issued in any private placement in which Stonegate participates. Moreover, Advaxis has agreed to indemnify Stonegate for certain liabilities, including liabilities under the Securities Act of 1933 as amended (the “Securities Act”).
Shares of the Company’s stock, issued and issuable under the aforementioned engagement, have not been registered under the Securities Act. Accordingly, these securities may not be offered or sold in the United States except pursuant to an effective registration statement or an applicable exemption from the registration requirements of the Securities Act. This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any jurisdiction in which an offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of such jurisdiction.
Forward-Looking Statements
Certain statements contained in this press release are forward-looking statements that involve risks and uncertainties. The statements contained herein that are not purely historical are forward looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements deal with the Company’s current plans, intentions, beliefs and expectations and statements of future economic performance. Forward-looking statements involve known and unknown risks and uncertainties that may cause the Company's actual results in future periods to differ materially from what is currently anticipated. Factors that could cause or contribute to such differences include those discussed from time to time in reports filed by the Company with the Securities and Exchange Commission. The Company cannot guarantee its future results, levels of activity, performance or achievements.